Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-319 in Relapsed or Refractory B-cell Lymphoma
NCT04056975Phase 1Unknown
- Sponsor
- Evive Biotech
- Start
- Sep 2019
- Primary completion
- Sep 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of A-319 in B cell lymphoma, sponsored by Evive Biotech. Primary endpoints: Incidence and Characteristics of Serious Adverse Events (SAE) and Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT). Status: unknown.
02
Drugs
A-319
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04056975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056975.